CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.

Favored by venture capital funds, Silicon Valley Bank has served biotech firms conducting transactions in the US. But its collapse is generating a ripple effect on Chinese start-ups already hard hit by a funding crunch.

China's just-concluded National Congress elected new senior government leadership, but shifting top-level policy priorities and a worsening wider operating environment mean observers are worried about continued growth and ongoing pressures on drug pricing.

Previously jailed gene editing scientist Jiankui He was absent from a recent international genome editing summit, but his renewed activities are generating new concerns five years after the Chinese researcher shocked the world by announcing the birth of gene-edited babies.  

Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.

Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.